Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells

HSP90 inhibitors, such as 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) which is currently in phase II/III clinical trials, are promising new anticancer agents. Here, we explored acquired resistance to HSP90 inhibitors in glioblastoma, a primary brain tumor with poor prognosis. Gliob...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Gaspar, Nathalie, Sharp, Swee Y, Pacey, Simon, Jones, Chris, Walton, Michael, Vassal, Gilles, Eccles, Suzanne, Pearson, Andrew, Workman, Paul
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2652695/
https://ncbi.nlm.nih.gov/pubmed/19244114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-08-3131
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky